Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zomig migraine therapy is priced by Zeneca at 50% discount to Glaxo high-dose sumatriptan in U.K.

Executive Summary

ZENECA ZOMIG PRICED AT 50% DISCOUNT TO GLAXO's IMIGRAN IN THE U.K.: six tablets of the recommended single dose of Zomig (zolmitriptan), 2.5 mg, sell for [pound]24 (about $38), while six 100 mg Imigran (sumatriptan) tablets have a U.K. National Health Service net cost of [pound]48. Zeneca introduced Zomig into the U.K. market in April, indicated "for the acute treatment of migraine with or without aura"; it launched in Sweden in May.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030709

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel